BioMarin Pharmaceuticals BMRN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| ALDURAZYME | $196.27M-0.7% | $208.51M+13.4% | $198.16M+5.6% | $215.48M+65.3% | $197.6M+49.6% | |
| BRINEURA | $193.14M+13.3% | $186.4M+10.2% | $184.73M+12.0% | $173.78M+2.8% | $170.4M+5.3% | |
| KUVAN | $98.27M-10.8% | $99.53M-17.7% | $104.52M-19.2% | $108.61M-24.6% | $110.13M-33.7% | |
| NAGLAZYME | $501.18M+2.7% | $485.4M+1.2% | $475.18M+1.6% | $485.06M+9.0% | $488.25M+21.2% | |
| PALYNZIQ | $429.6M+15.3% | $433.31M+22.0% | $408.4M+19.3% | $390.25M+18.0% | $372.61M+17.4% | |
| ROCTAVIAN | $27.77M-22.3% | $35.64M+36.7% | $33.44M+83.9% | $37.49M+219% | $35.73M+724% | |
| Royalty and other revenues | $49.12M+11.8% | $53.49M+20.3% | $49.93M+8.9% | $46.48M-1.2% | $43.95M-7.9% | |
| VIMIZIM | $813.91M+10.6% | $792.05M+7.1% | $777.62M+7.4% | $773.02M+9.6% | $735.61M+4.4% | |
| VOXZOGO | $933.05M+17.2% | $926.92M+26.1% | $862.03M+28.2% | $833.43M+37.6% | $795.96M+48.8% | |
| R&D by Product | ||||||
| Later-stage clinical programs | $330.22M+689% | $308.33M+175% | $288.86M+145% | $47.29M-61.7% | $41.87M-68.2% | |
| Marketed products | $231.25M-9.3% | $229.89M-19.5% | $231.35M-22.2% | $237.15M-21.0% | $254.96M-15.8% | |
| Research and early pipeline | $380.53M-5.8% | $383.71M-11.6% | $382.81M-10.9% | $394M-6.9% | $404.1M-2.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BioMarin Pharmaceuticals break its business down?
- BioMarin Pharmaceuticals (BMRN) reports total revenues by product across 9 parts — ALDURAZYME, BRINEURA, KUVAN, NAGLAZYME and PALYNZIQ. Each is extracted from the segment footnotes and tracked over time.
- Where does BioMarin Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BioMarin Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
